154 related articles for article (PubMed ID: 38653401)
21. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
[TBL] [Abstract][Full Text] [Related]
22. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
Holst JJ; Rosenkilde MM
J Clin Endocrinol Metab; 2020 Aug; 105(8):e2710-6. PubMed ID: 32459834
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents.
Moss CE; Marsh WJ; Parker HE; Ogunnowo-Bada E; Riches CH; Habib AM; Evans ML; Gribble FM; Reimann F
Diabetologia; 2012 Nov; 55(11):3094-103. PubMed ID: 22872212
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut.
Morrow NM; Morissette A; Mulvihill EE
Peptides; 2024 Jun; 176():171200. PubMed ID: 38555054
[TBL] [Abstract][Full Text] [Related]
25. Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Adriaenssens AE; Biggs EK; Darwish T; Tadross J; Sukthankar T; Girish M; Polex-Wolf J; Lam BY; Zvetkova I; Pan W; Chiarugi D; Yeo GSH; Blouet C; Gribble FM; Reimann F
Cell Metab; 2019 Nov; 30(5):987-996.e6. PubMed ID: 31447324
[TBL] [Abstract][Full Text] [Related]
26. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
Pathak V; Vasu S; Flatt PR; Irwin N
Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
[TBL] [Abstract][Full Text] [Related]
27. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
28. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
[TBL] [Abstract][Full Text] [Related]
29. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
Knerr PJ; Mowery SA; Douros JD; Premdjee B; Hjøllund KR; He Y; Kruse Hansen AM; Olsen AK; Perez-Tilve D; DiMarchi RD; Finan B
Mol Metab; 2022 Sep; 63():101533. PubMed ID: 35809773
[TBL] [Abstract][Full Text] [Related]
30. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
31. Novel extrapancreatic effects of incretin.
Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
[TBL] [Abstract][Full Text] [Related]
32. The incretins: a link between nutrients and well-being.
Burcelin R
Br J Nutr; 2005 Apr; 93 Suppl 1():S147-56. PubMed ID: 15877888
[TBL] [Abstract][Full Text] [Related]
33. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
34. Incretin actions beyond the pancreas: lessons from knockout mice.
Yabe D; Seino Y
Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
[TBL] [Abstract][Full Text] [Related]
35. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
36. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
Mathiesen DS; Bagger JI; Bergmann NC; Lund A; Christensen MB; Vilsbøll T; Knop FK
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443356
[TBL] [Abstract][Full Text] [Related]
37. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
38. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
39. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
[TBL] [Abstract][Full Text] [Related]
40. Genetic determinants of circulating GIP and GLP-1 concentrations.
Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
